Spyre Q1 net loss $69M; SPY001 hits primary endpoint; cash runway to H2 2029

Spyre Therapeutics, Inc.

2026-Q1 EPS reported -$0.74

Net loss of $69.0M in Q1 2026 vs $44.8M in Q1 2025; R&D expenses $60.4M (up from $41.6M).
Pro forma cash $1,176.8M as of March 31, 2026, including $435.3M net from April 2026 offering; runway into H2 2029.
SPY001 achieved primary endpoint in Part A of SKYLINE: RHI score reduction 9.2 points (p<0.0001); clinical remission 40%, endoscopic improvement 51%.
SPY001 safety consistent with α4β7 class; RA sub-study of SKYWAY over-enrolled, topline readout accelerated to Q3 2026.
On track for 6 proof-of-concept readouts in 2026 across SKYLINE and SKYWAY Phase 2 trials.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Spyre Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001636282-26-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.